Anticonceptivos orales para los quistes ováricos funcionales
Information
- DOI:
- https://doi.org/10.1002/14651858.CD006134.pub5Copy DOI
- Database:
-
- Cochrane Database of Systematic Reviews
- Version published:
-
- 29 April 2014see what's new
- Type:
-
- Intervention
- Stage:
-
- Review
- Cochrane Editorial Group:
-
Cochrane Fertility Regulation Group
- Copyright:
-
- Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Article metrics
Altmetric:
Cited by:
Authors
Contributions of authors
D Grimes (while at FHI 360) developed the idea, registered the title, and edited the review. D Grimes also conducted the second data abstraction for the 2009 and 2011 updates. For the initial review, L Jones (while at FHI 360) and L Lopez conducted the data abstraction and drafted the manuscript. K Schulz edited the review and provided statistical oversight. L Lopez conducted the updates from 2009 to 2014 and incorporated new trials (when applicable).
Sources of support
Internal sources
-
No sources of support supplied
External sources
-
US Agency for International Development, USA.
Support for conducting the review and updates at FHI 360 (through 2011)
-
National Institute of Child Health and Human Development, USA.
Support for conducting the review and updates at FHI 360
Declarations of interest
D Grimes has consulted with the pharmaceutical companies Bayer Healthcare Pharmaceuticals and Merck & Co, Inc.
Acknowledgements
Carol Manion of FHI 360 assisted with the literature searches.
Version history
| Published | Title | Stage | Authors | Version |
| 2014 Apr 29 | Oral contraceptives for functional ovarian cysts | Review | David A Grimes, LaShawn B. Jones, Laureen M Lopez, Kenneth F Schulz | |
| 2011 Sep 07 | Oral contraceptives for functional ovarian cysts | Review | David A Grimes, LaShawn B. Jones, Laureen M Lopez, Kenneth F Schulz | |
| 2009 Apr 15 | Oral contraceptives for functional ovarian cysts | Review | David A Grimes, LaShawn B. Jones, Laureen M Lopez, Kenneth F Schulz | |
| 2006 Oct 18 | Oral contraceptives for functional ovarian cysts | Review | David A Grimes, LaShawn B. Jones, Laureen M Lopez, Kenneth F Schulz | |
| 2006 Jul 19 | Oral contraceptives for functional ovarian cysts | Protocol | David A Grimes, LaShawn B. Jones, Laureen M Lopez, Kenneth F Schulz | |
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
Medical Subject Headings Check Words
Adult; Female; Humans;
PICOs
Comparison 1 Norethindrone 1 mg plus mestranol 50 μg daily versus expectant management, Outcome 1 Resolution of cyst within nine weeks.
Comparison 2 Desogestrel 150 μg plus ethinyl estradiol 30 μg taken cyclically versus expectant management, Outcome 1 Resolution of cyst by last follow up (10 or 12 weeks).
Comparison 3 Desogestrel 150 μg plus ethinyl estradiol 20 μg taken daily versus expectant management, Outcome 1 Resolution of cyst by six months.
Comparison 4 Levonorgestrel 100 μg plus ethinyl estradiol 20 μg taken cyclically versus expectant management, Outcome 1 Resolution of cyst by 12 weeks.
Comparison 5 Levonorgestrel 125 μg plus ethinyl estradiol 50 μg taken cyclically versus expectant management, Outcome 1 Resolution of cyst within one menstrual cycle.
Comparison 6 Levonorgestrel 150 μg plus ethinyl estradiol 30 μg taken cyclically versus expectant management, Outcome 1 Resolution of cyst by last follow up (second or third month).
Comparison 6 Levonorgestrel 150 μg plus ethinyl estradiol 30 μg taken cyclically versus expectant management, Outcome 2 Cyst volume after third month.
Comparison 7 Levonorgestrel 250 μg plus ethinyl estradiol 50 μg taken cyclically versus expectant management, Outcome 1 Resolution of cyst by 10 weeks.
Comparison 8 Levonorgestrel 50/75/125 μg plus ethinyl estradiol 30/40/30 μg taken cyclically versus expectant management, Outcome 1 Resolution of cyst by 10 weeks.
Comparison 9 Levonorgestrel 100 μg plus ethinyl estradiol 20 μg versus desogestrel 150 μg plus ethinyl estradiol 30 μg, Outcome 1 Regression of cyst by 4 weeks.
Comparison 9 Levonorgestrel 100 μg plus ethinyl estradiol 20 μg versus desogestrel 150 μg plus ethinyl estradiol 30 μg, Outcome 2 Regression of cyst by 12 weeks.
Comparison 10 Levonorgestrel 100 μg plus ethinyl estradiol 20 μg versus placebo, Outcome 1 Regression of cyst by 4 weeks.
Comparison 10 Levonorgestrel 100 μg plus ethinyl estradiol 20 μg versus placebo, Outcome 2 Regression of cyst by 12 weeks.
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Resolution of cyst within nine weeks Show forest plot | 1 | 41 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Resolution of cyst by last follow up (10 or 12 weeks) Show forest plot | 2 | 76 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.52 [0.46, 5.00] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Resolution of cyst by six months Show forest plot | 1 | 141 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.62 [0.27, 1.42] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Resolution of cyst by 12 weeks Show forest plot | 1 | 42 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.71 [0.45, 6.51] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Resolution of cyst within one menstrual cycle Show forest plot | 1 | 54 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.72 [0.14, 3.57] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Resolution of cyst by last follow up (second or third month) Show forest plot | 2 | 112 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.19 [0.54, 2.60] |
| 2 Cyst volume after third month Show forest plot | 1 | 45 | Mean Difference (IV, Fixed, 95% CI) | 3.20 [‐0.87, 7.27] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Resolution of cyst by 10 weeks Show forest plot | 1 | 34 | Odds Ratio (M‐H, Fixed, 95% CI) | 3.18 [0.12, 83.76] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Resolution of cyst by 10 weeks Show forest plot | 1 | 35 | Odds Ratio (M‐H, Fixed, 95% CI) | 3.36 [0.13, 88.39] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Regression of cyst by 4 weeks Show forest plot | 1 | 124 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.15 [0.55, 2.38] |
| 2 Regression of cyst by 12 weeks Show forest plot | 1 | 124 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.41 [0.55, 3.64] |
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| 1 Regression of cyst by 4 weeks Show forest plot | 1 | 124 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.93 [0.44, 1.95] |
| 2 Regression of cyst by 12 weeks Show forest plot | 1 | 124 | Odds Ratio (M‐H, Fixed, 95% CI) | 1.27 [0.49, 3.32] |
